Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

ClinicalTrials.gov ID: NCT02846532

Public ClinicalTrials.gov record NCT02846532. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment (Part A) and to evaluate the safety and efficacy of rivaroxaban, administered twice daily (exposure matched to rivaroxaban 10 milligram \[mg\] once daily in adults) compared to acetylsalicylic acid (ASA), given once daily (approximately 5 milligram per kilogram \[mg/kg\]) for thromboprophylaxis in pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment.

Study identification

NCT ID
NCT02846532
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
112 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
2 Years to 8 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2016 (Actual)
Primary completion
Jul 16, 2020 (Actual)
Completion
Jul 16, 2020 (Actual)
Last update posted
Mar 30, 2025

2016 – 2020

United States locations

U.S. sites
17
U.S. states
16
U.S. cities
17
Facility City State ZIP Site status
Not listed Los Angeles California — —
Not listed Gainesville Florida — —
Not listed Oak Lawn Illinois — —
Not listed Indianapolis Indiana — —
Not listed Iowa City Iowa — —
Not listed Baltimore Maryland — —
Not listed Boston Massachusetts — —
Not listed Minneapolis Minnesota — —
Not listed Omaha Nebraska — —
Not listed Durham North Carolina — —
Not listed Cincinnati Ohio — —
Not listed Hershey Pennsylvania — —
Not listed Philadelphia Pennsylvania — —
Not listed Memphis Tennessee — —
Not listed Houston Texas — —
Not listed Salt Lake City Utah — —
Not listed Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02846532, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2025 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02846532 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →